Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Alzheimer`s Disease Neuroimaging Initiative 2

Study:

Alzheimer`s Disease Neuroimaging Initiative 2

Rationale:

n/a

Purpose:

The purpose of this study is to build upon the information obtained in the original Alzheimer`s Disease Neuroimaging Initiative (ADNI1) and ADNI-GO (Grand Opportunity; a study funded through an NIH grant under the American Recovery and Reinvestment Act), to examine how brain imaging technology can be used with other tests to measure the progression of mild cognitive impairment (MCI) and early Alzheimer`s disease (AD). ADNI2 seeks to inform the neuroscience of AD. This information will aid in the early detection of AD, and in measuring the effectiveness of treatments in future clinical trials.

Study Status: Recruiting

Recruiting:
Michelle Sholar, BA 702-483-6026 sholarm@ccf.org

Condition Intervention Phase
Mild Cognitive Impairment (MCI)
Alzheimer`s Disease		 n/a N/A

Verified by Alzheimer`s Disease Cooperative Study (ADCS) May, 2013

Sponsored by: Alzheimer`s Disease Cooperative Study (ADCS)
Information provided by: Alzheimer`s Disease Cooperative Study (ADCS)
ClinicalTrials.gov identifier: NCT01231971

Study Type: Interventional

Study Design: Observational Model: Case Control, Time Perspective: Prospective

Cleveland Clinic Lou Ruvo Center for Brain Health
Las Vegas, Nevada 89106
United States

Ronald Petersen, MD, PhD., Principal Investigator
Michael W. Weiner, MD., Principal Investigator
Paul S. Aisen, MD., Principal Investigator

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.